Company: HROW
Filing Date: 2025-11-18
Form Type: 8-K
Source: 0001493152-25-023988
Chunk: 0

Company: HARROW, INC.
Filing Date: 2025-11-18
Form: 8-K
Item: Item 2.01
Chunk 0
---
Item
2.01 Completion of Acquisition or Disposition of Assets.

On
November 17, 2025, Harrow, Inc. (the “ Company”) completed the previously announced acquisition of Melt Pharmaceuticals, Inc.
(“ Melt”) pursuant to the Agreement and Plan of Merger, dated September 24, 2025 (the “ Merger Agreement”), by
and among the Company, Harrow Acquisition Sub, Inc., Melt, and the stockholder representative.

The
material terms of the Merger Agreement and the related milestone payment agreement were previously described in the Company’s Current
Report on Form 8-K filed on September 26, 2025, which description is incorporated herein by reference.

At
closing, the Company paid approximately $4.3 million in cash as initial consideration for the remaining equity interests of Melt. The
contingent regulatory and commercial milestone payments described in the Company’s September 26, 2025 Form 8-K remain unchanged.

All
closing conditions under the Merger Agreement were satisfied or waived, and the merger became effective on November 17, 2025.

Item
3.02 Unregistered Sales of Equity Securities.